Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy ImmunoGen stock
Own ImmunoGen stock in just a few minutes.
ImmunoGen, Inc is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 79 staff and has a trailing 12-month revenue of around USD$132.3 million.
How to buy shares in ImmunoGen
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for ImmunoGen. Find the stock by name or ticker symbol: IMGN. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ImmunoGen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ImmunoGen, depending on your broker.
- Check in on your investment. Congratulations, you own a part of ImmunoGen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
ImmunoGen share price
Use our graph to track the performance of IMGN stocks over time.ImmunoGen shares at a glance
Information last updated 2021-04-08.
| 52-week range | USD$3.335 - USD$10.88 |
|---|---|
| 50-day moving average | USD$8.6803 |
| 200-day moving average | USD$6.8117 |
| Wall St. target price | USD$10.21 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-1.19 |
Buy ImmunoGen shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy ImmunoGen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ImmunoGen financials
| Revenue TTM | USD$132.3 million |
|---|---|
| Gross profit TTM | USD$17.7 million |
| Return on assets TTM | -4.42% |
| Return on equity TTM | -659.86% |
| Profit margin | -33.54% |
| Book value | $0.459 |
| Market capitalisation | USD$1.6 billion |
TTM: trailing 12 months
Shorting ImmunoGen shares
There are currently 22.3 million ImmunoGen shares held short by investors – that's known as ImmunoGen's "short interest". This figure is 2.5% down from 22.9 million last month.
There are a few different ways that this level of interest in shorting ImmunoGen shares can be evaluated.
ImmunoGen's "short interest ratio" (SIR)
ImmunoGen's "short interest ratio" (SIR) is the quantity of ImmunoGen shares currently shorted divided by the average quantity of ImmunoGen shares traded daily (recently around 2.7 million). ImmunoGen's SIR currently stands at 8.16. In other words for every 100,000 ImmunoGen shares traded daily on the market, roughly 8160 shares are currently held short.
However ImmunoGen's short interest can also be evaluated against the total number of ImmunoGen shares, or, against the total number of tradable ImmunoGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmunoGen's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 ImmunoGen shares in existence, roughly 110 shares are currently held short) or 0.1234% of the tradable shares (for every 100,000 tradable ImmunoGen shares, roughly 123 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ImmunoGen.
Find out more about how you can short ImmunoGen stock.
ImmunoGen share dividends
We're not expecting ImmunoGen to pay a dividend over the next 12 months.
ImmunoGen share price volatility
Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $3.335 up to $10.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 1.38. This would suggest that ImmunoGen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ImmunoGen overview
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert